FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Tuesday, March 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Regeneron Contacts:

 

Media Relations

Sharon Chen

Tel: +1 (914) 847-1546

Sharon.Chen@regeneron.com

Investor Relations

Mark Hudson

Tel: +1 (914) 847-3482 

Mark.Hudson@regeneron.com 

 

Sanofi Contacts:

 

Media Relations

Ashleigh Koss

Tel: +1 (908) 981-8745

Ashleigh.Koss@sanofi.com

Investor Relations

George Grofik

Tel: +33 (0)1 53 77 45 45

ir@sanofi.com 



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store